U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Malignant Mesothelioma

MedGen UID:
1659783
•Concept ID:
C4725811
•
Neoplastic Process

Definition

Malignant mesothelioma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Malignant Mesothelioma

Professional guidelines

PubMed

Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT, Egbune C
Cancer Treat Res 2023;185:79-89. doi: 10.1007/978-3-031-27156-4_5. PMID: 37306905
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R, Shimoi T, Sudo K, Noguchi E, Nagata Y, Sawada R, Takashima A, Boku N, Yonemori K
BMC Cancer 2021 Mar 20;21(1):294. doi: 10.1186/s12885-021-08025-x. PMID: 33743636Free PMC Article
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
Fizazi K, John WJ, Vogelzang NJ
Semin Oncol 2002 Feb;29(1):77-81. doi: 10.1053/sonc.2002.30233. PMID: 11836672

Recent clinical studies

Etiology

Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE
J Interferon Res 1990 Oct;10(5):531-4. doi: 10.1089/jir.1990.10.531. PMID: 2273299

Therapy

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M
Cancer Immunol Immunother 2015 Jan;64(1):105-12. Epub 2014 Sep 19 doi: 10.1007/s00262-014-1609-9. PMID: 25233793
Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE
J Interferon Res 1990 Oct;10(5):531-4. doi: 10.1089/jir.1990.10.531. PMID: 2273299

Prognosis

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M
Cancer Immunol Immunother 2015 Jan;64(1):105-12. Epub 2014 Sep 19 doi: 10.1007/s00262-014-1609-9. PMID: 25233793

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...